Wiley content to power OpenEvidence clinical AI platform
Wiley has announced a strategic partnership with medical AI platform OpenEvidence that will integrate a large portfolio of the publisher’s peer-reviewed scientific and medical content into the platform used by physicians at the point of care.
Through the partnership, clinicians using OpenEvidence will gain access to evidence drawn from hundreds of Wiley journals and reference works across a range of medical specialties to support clinical decision-making.
The collaboration reflects growing interest across the healthcare and scholarly publishing sectors in ensuring that AI systems used in clinical settings are grounded in authoritative, peer-reviewed research rather than unverified web sources.
Medical knowledge is estimated to double every 73 days, yet historically it has taken an average of 17 years for published research to be translated into clinical practice. OpenEvidence was designed to address this gap by training specialised AI models on peer-reviewed literature and ensuring that every response is linked to verifiable sources.
Daniel Nadler, founder of OpenEvidence, said: “The hard problem in medicine right now isn’t just generating new knowledge. We are living through a golden age of biomedical research. The hard problem is also that it takes 17 years for a fraction of that research to reach the bedside. Wiley is an ideal partner in solving this problem for physicians. The depth and breadth of Wiley’s content reinforce the advantages of OpenEvidence for physicians, and that compounds over time.”
Under the agreement, Wiley will license a comprehensive portfolio of scientific and medical content to OpenEvidence. This includes the Cochrane Database of Systematic Reviews, widely regarded as a gold-standard source of evidence syntheses used to inform clinical guidelines worldwide, as well as Cochrane Clinical Answers, which provides curated clinical insights derived from Cochrane reviews.
“Cochrane systematic reviews are relied upon by evidence users worldwide, from patients and healthcare professionals to guideline-setters and policymakers,” said Karla Soares-Weiser, CEO of Cochrane. “AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence.”
The licensed portfolio will also include more than 400 Wiley journals and books, alongside major reference works such as Holland-Frei Cancer Medicine, Rook’s Dermatology Handbook, and Yamada’s Textbook of Gastroenterology. These resources span multiple specialties including cardiology, endocrinology, geriatrics, hematology, internal medicine, neurology, obstetrics, oncology, psychiatry and rheumatology.
According to the companies, the content will be incorporated into OpenEvidence’s evidence layer and cited transparently within responses. The platform says it is already trusted by more than 40% of physicians in the United States.
For clinicians, the partnership aims to expand access to reliable evidence directly within their clinical workflow. By broadening the available literature, the companies say the platform will help physicians address complex or unusual clinical questions without needing to leave the point-of-care environment.
Matt Kissner, president and CEO of Wiley, concluded: “At the end of the day, we believe doctors will be able to make better decisions because we’re bringing Wiley’s vast portfolio of peer-reviewed scientific and medical content into OpenEvidence, where those decisions are getting made. We’re excited about this partnership, which reflects our broader commitment to integrating trusted scientific knowledge into the technologies driving innovation across healthcare and life sciences.”